Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA
Crossref DOI link: https://doi.org/10.1136/bmjdrc-2019-000704
Published Online: 2019-11-07
Published Print: 2019-11
Update policy: https://doi.org/10.1136/crossmarkpolicy
Singhal, Mukul
Tan, Hiangkiat
Coleman, Craig I
Han, Michelle
Nguyen, Chi
Ingham, Michael http://orcid.org/0000-0001-9462-9165
Funding for this research was provided by:
Janssen Scientific Affairs, LLC